Pushkala Aripaka, Lucy Marks

(Reuters) – A large British study on mixing COVID-19 vaccinations found people have a stronger immune response to AstraZeneca (NASDAQ) and Pfizer BioNTech shots, respectively. Moderna (NASDAQ:) Nine weeks later, according the Monday results.

Matthew Snape (an Oxford professor who led the Com-COV2 trial) said that there was a “really good immune response across all the board …,, in fact, greater than the threshold set forth by Oxford-AstraZeneca vaccination two doses.”

Flexible dosing is a promising option for poor and middle-income countries. They may be able to use different brands in their first shot and then switch to the second shot if they run out or become unstable.

Snape stated, “I believe the data from the study will be particularly interesting and valuable for low-and middle-income countries that are still rolling out two doses vaccines.”

“We are showing…that you don’t have to get the same vaccine every time. It is possible to use multiple vaccines to speed up the delivery of the programme.

It is possible to get the AstraZeneca Oxford vaccine if you also have a Moderna. Novavax Researchers at Oxford found that two doses of AstraZeneca Oxford induced higher levels of antibodies and stronger T-cell reactions than the shot.

A study of 170 volunteers found that two Pfizer BioNTech courses were better than one Moderna shot.

Novavax was followed by Pfizer BioNTech, which produced more antibodies than two-dose Oxford AstraZeneca. But this schedule still produced lower antibody and T cell responses than two-dose Pfizer BioNTech.

The study by Oxford University, published in Lancet’s medical journal, found that there was no evidence of safety concern.

A mix of match was used by many countries long before reliable data became available. This is because nations faced high infection rates, limited supplies, and slow vaccinations over safety concerns.

The long-term effectiveness of vaccines is being questioned. In the face of rising cases, booster doses have been considered. Omicron and Delta are two new variants that have increased pressure on vaccination programs to be speeded up.

Participants’ blood was tested for Wild-Type, Beta, and Delta variants. Researchers at the ComCOV2 study stated that although vaccines have shown a decline in effectiveness against variants over time, this trend is consistent with mixed-course courses.

Implementing vaccines with technology coming from multiple platforms, such as Google and Facebook. Pfizer (NYSE:) Moderna’s genomic DNA and AstraZeneca’s viral vector are new, as is Novavax’s protein shot.

According to him, the findings could lead to new ways of immunising against other diseases.

In accordance with June’s conclusions, the study found that the first AstraZeneca Oxford vaccine administered followed by the remaining candidates generated an especially robust response.

The study was designed as a so-called “non-inferiority” study – the intent is to demonstrate that mixing is not substantially worse than the standard schedules – and compares the immune system responses to the gold-standard responses reported in previous clinical trials of each vaccine.